NCT07509034 2026-04-16
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
Clinical Trials
22 trialsNCT07532746 2026-04-16
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
Phase 1 Not yet recruiting
NCT07493174 2026-04-15
Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07485504 2026-03-20
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1 Not yet recruiting
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07343934 2026-01-15
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07331064 2026-01-09
GABRIEL
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07316920 2026-01-06
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07316907 2026-01-05
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07306832 2025-12-29
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
AbbVie
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06970496 2025-11-20
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT07200479 2025-10-01
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07137637 2025-08-22
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase 1 Not yet recruiting
NCT07113496 2025-08-13
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Not yet recruiting
NCT06647329 2024-10-17
CAR-T Therapy
Zhengzhou University
Phase 1 Not yet recruiting
NCT06641648 2024-10-15
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
Peking University First Hospital
Phase 1 Not yet recruiting
NCT06500507 2024-07-15
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06412458 2024-05-14
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT05582590 2024-01-16
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
Phase 1 Not yet recruiting
NCT06093698 2023-10-23
A-337
ITabMed Co., Ltd.
Phase 1 Not yet recruiting